CoChat

Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis

Open access
Marik, Paul E., Cavallazzi, Rodrigo · 2015 · PLOS ONE

The DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Patients who have had an unprovoked deep venous thrombosis (DVT) or pulmonary embolus (PE) are at a high risk for recurrent venous thromboembolism (VTE). Extended "life-long" anticoagulation has been recommended in these patients. However, the risk benefit ratio of this approach is controversial and the role of the direct oral anticoagulants (DOACs) and aspirin is unclear. Furthermore, in some patients with a "weak provoking factor" there is clinical equipoise regarding continuation or cessation of anticoagulant therapy after treatment of the acute VTE event. OBJECTIVE: A systematic review and meta-analysis to determine the risks (major bleeding) and benefits (recurrent VTE and mortality) of extended anticoagulation with vitamin k antagonists (VKA), DOACs and aspirin in patients with an unprovoked VTE and in those patients with clinical equipoise regarding continuation or cessation of anticoagulant therapy. In addition, we sought to determine the risk of recurrent VTE events once extended anti-thrombotic therapy was discontinued. DATA SOURCES: MEDLINE, Cochrane Register of Controlled Trials, citation review of relevant primary and review articles. STUDY SELECTION: Randomized placebo-controlled trials (RCTs) that compared the risk of recurrent VTE in patients with an unprovoked DVT or PE who had been treated for at least 3 months with a VKA or a DOAC and were then randomized to receive an oral anti-thrombotic agent or placebo for at least 6 additional months. We included studies that included patients in whom clinical equipoise existed regarding the continuation or cessation of anticoagulant therapy. DATA EXTRACTION: Independent extraction of articles by both authors using predefined data fields, including study quality indicators. Data were abstracted on study size, study setting, initial event (DVT or PE), percentage of patients where the initial VTE event was unprovoked, the number of recurrent VTE events, major bleeds and mortality during the period of extended anticoagulation in the active treatment and placebo arms. In addition, we recorded the event rate once extended treatment was stopped. Meta-analytic techniques were used to summarize the data. Studies were grouped according to the type of anti-thrombotic agent. DATA SYNTHESIS: Seven studies which enrolled 6778 patients met our inclusion criteria; two studies evaluated the extended use of Coumadin, three studies evaluated a DOAC and two studies evaluated the use of aspirin. The duration of followup varied from 6 to 37 months. In the Coumadin and aspirin studies 100% of the randomized patients had an unprovoked VTE, while in the DOAC studies between 73.5% and 93.2% of the VTE events were unprovoked. In the control group recurrent VTE occurred in 9.7% of patients compared to 2.8% in the active treatment group (OR 0.21; 95% CI 0.11-0.42, p<0.0001). VKA, DOACs and aspirin significantly reduced the risk of recurrent VTE, with VKA and DOACs being significantly more effective than aspirin. Major bleeding events occurred in 12 patients in the control group (0.4%) and 25 of 3815 (0.6%) patients in the active treatment group (OR 1.64; 95% CI 0.69-3.90, NS). There were 39 (1.3%) deaths in control patients and 33 (0.9%) deaths in the anti-thrombotic group during the treatment period (OR 0.73; 95% CI 0.40-1.33, NS). Patients whose initial VTE event was a PE were more likely to have a recurrent PE than a DVT. The annualized event rate after discontinuation of extended antithrombotic therapy was 4.4% in the control group and 6.5% in the active treatment arm. CONCLUSIONS: VKA, DOACs and aspirin significantly reduced the risk of recurrent VTE, with DOACs and VKA being more effective than aspirin. The decision regarding life-long anticoagulation following an unprovoked DVT or PE should depend on the patients' risk for recurrent PE as well as the patients' values and preferences.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0143252

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Flow-chart of studies evaluated for inclusion in meta-analysis.
Fig 1 Flow-chart of studies evaluated for inclusion in meta-analysis.CC BY · PubMed Central
Fig 2 Comparison of the risk of recurrent thromboembolic events during the study period for patients receiving anticoagulant (intervention) versus control (placebo). Studies are grouped by type of anticoagulant. Weight is the relative contribution of each study to the overall treatment effect (odds risk ratio and 95% confidence interval) on a log scale assuming a random effects model.
Fig 2 Comparison of the risk of recurrent thromboembolic events during the study period for patients receiving anticoagulant (intervention) versus control (placebo). Studies are grouped by type of anticoagulant. Weight is the relative contribution of each study to the overall treatment effect (odds risk ratio and 95% confidence interval) on a log scale assuming a random effects model.CC BY · PubMed Central
Fig 3 Comparison of the risk of major bleeds during study period for patients receiving anticoagulant (intervention) versus control (placebo). Studies are grouped by type of anticoagulant. Weight is the relative contribution of each study to the overall treatment effect (odds risk ratio and 95% confidence interval) on a log scale assuming a random effects model.
Fig 3 Comparison of the risk of major bleeds during study period for patients receiving anticoagulant (intervention) versus control (placebo). Studies are grouped by type of anticoagulant. Weight is the relative contribution of each study to the overall treatment effect (odds risk ratio and 95% confidence interval) on a log scale assuming a random effects model.CC BY · PubMed Central
Fig 4 Comparison of the risk of mortality during study period for patients receiving anticoagulant (intervention) versus control (placebo). Studies are grouped by type of anticoagulant. Weight is the relative contribution of each study to the overall treatment effect (odds risk ratio and 95% confidence interval) on a log scale assuming a random effects model.
Fig 4 Comparison of the risk of mortality during study period for patients receiving anticoagulant (intervention) versus control (placebo). Studies are grouped by type of anticoagulant. Weight is the relative contribution of each study to the overall treatment effect (odds risk ratio and 95% confidence interval) on a log scale assuming a random effects model.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 55

Metadata

Authors
Marik, P. E., & Cavallazzi, R.
Affiliations
  • Eastern Virginia Medical School (US)
  • University of Louisville (US)
Corresponding author
Marik, Paul E.
Venue
PLOS ONE
Published
2015-11-20
Volume
10
Issue
11
Pages
e0143252
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2180178994
Cited by
53
References
43
Citations by year
2026: 2 · 2025: 4 · 2024: 2 · 2023: 3 · 2022: 5 · 2021: 3 · 2020: 10 · 2019: 4 · 2018: 7 · 2017: 5 · 2016: 7
FWCI
1.66
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Keywords
long-term anticoagulation, venous thromboembolism, deep vein thrombosis, pulmonary embolism, aspirin, direct oral anticoagulants, vitamin K antagonists, secondary prevention, recurrent venous thromboembolism, major bleeding, mortality, unprovoked thrombosis, clinical equipoise
MeSH terms
Anticoagulants, Aspirin, Data Collection, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Recurrence, Risk Factors, Sex Factors, Thromboembolism, Vitamin K, Warfarin, Randomized Controlled Trials as Topic, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis. https://app.cochat.ai/papers/10.1371/journal.pone.0143252
The paper
Marik, P. E., & Cavallazzi, R. (2015). Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis. PLOS ONE. https://doi.org/10.1371/journal.pone.0143252

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.